Thursday , May 25 2017
Home / Hemophilia

Hemophilia

Shire’s Hemophilia Candidate Using Xenetic Technology Platform Fails in Phase 1/2 Trial

LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has received an update on the Phase 1/2 clinical study conducted by its partner Shire, evaluating …

Read More »

Sangamo’s Hemophilia A Gene Therapy Candidate Receives Fast Track Status from the FDA

RICHMOND, Calif., May 16, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SB-525, the Company’s clinical stage cDNA gene therapy candidate for hemophilia A, which is being developed as part of an exclusive, global …

Read More »

Pfizer Enters Gene Therapy Deal with Sangamo, Expanding Hemophilia Pipeline

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo’s four lead product candidates, which Sangamo expects will enter the clinic this quarter. “Sangamo …

Read More »

Three Sangamo Clinical Programs Receive Special Regulatory Designations from the FDA

RICHMOND, Calif., May 4, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) of special regulatory designations for three of the Company’s clinical programs. Rare Pediatric Disease (RPD) designation …

Read More »

Genentech’s Hemophilia Drug Demonstrates Positive Interim Results in Late-Stage Study in Children

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII. At this interim analysis …

Read More »

Spark’s Hemophilia B Candidate Demonstrates Positive Early-Stage Data

PHILADELPHIA, April 06, 2017 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE) announced updated preliminary data today from 10 infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B. All participants have experienced consistent and sustained increases in factor IX activity following administration of the investigational therapy. …

Read More »

FDA Grants Breakthrough Therapy Designation to uniQure’s Investigational Hemophilia B Drug

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060,  its proprietary, investigational gene therapy in patients with severe hemophilia B, has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).  This designation …

Read More »

Takeda to Acquire ARIAD Pharmaceuticals for $5.2 Billion

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of …

Read More »

Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

December 22, 2016 01:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or …

Read More »

UT Austin Engineers Develop First-Ever Capsule to Treat Hemophilia

In the near future, hemophiliacs could be able to treat their disease by simply swallowing a capsule. Thanks to a breakthrough led by researchers in the Cockrell School of Engineering at The University of Texas at Austin, treatment for hemophilia can now be administered via a biodegradable system, a capsule, …

Read More »